Business Wire

NY-THE-BODY-SHOP

9.1.2023 07:16:30 CET | Business Wire | Press release

Share
‘No Say Day’: the Last Day Youth Voices Are Represented in Parliaments Around the World

Today is No Say Day - the last day in 2023 when young people’s voices are represented in parliaments around the world. This falls a week before world leaders and businesses gather in Davos for the World Economic Forum Annual Meeting. Often criticised for being out of touch, Davos is a prime example of the need for more youth voices in decision making spaces.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230108005001/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Antonia Tony-Fadipe, Inclusive Hiring Lead and The Body Shop Youth Collective member; Urvasi De Biasi, Activism Policy and Partnerships, The Body Shop; Lily Cannon, Activism Communications Manager, The Body Shop; Lucila San Martin, Global Activism Manager, The Body Shop (Photo: Business Wire)

Half of the world’s population is under 30, compared to just 2.6% of parliamentarians globally*. If this ratio were reflected in a year, youth voices would effectively go unheard after today. Just nine days into 2023, No Say Day is a stark demonstration of the fact that millions of young voices are excluded from decision-making spaces at a time when the world is facing extreme systemic challenges.

No Say Day is being marked as part of the Be Seen Be Heard campaign, led by The Body Shop in collaboration with the Office of the United Nations Secretary-General's Envoy on Youth to raise the voices of millions of young people in over 75 countries across six continents.

Public opinion is widely in favour of fairer political representation for young people. According to The Body Shop’s largest-ever global survey**, two thirds of people agree that the age balance in politics is wrong.

People across all age groups agree that political systems would be improved by giving young people a say in policy development. Young people are optimistic and determined to increase their involvement in public life. A third of those under age 30 surveyed would consider running for office, versus only a fifth of those over age 30.

Chris Davis, Global Sustainability and Activism Director at The Body Shop, said: “From climate change to economic instability and conflict, the world’s problems are too great to fall back on business-as-usual. Young people are energetic, thoughtful, and positive about the future – so it’s important their voices are seen and heard in parliaments around the world every day. This is clearly the preference of the public, who support a fairer approach to youth representation and trust young people’s views on the major issues of today.

“As world leaders and captains of industry gather in Davos next week, I urge them to work with young people to develop solutions to the problems we all face. Let’s make today the last No Say Day in our history.”

Jayathma Wickramanayake, the UN Secretary-General’s Envoy on Youth, said: “Young people are the experts of their own realities, and young people all over the world are making a difference every day by tackling issues that matter most to them. The idea that young people are change makers is not just a marketing campaign, it is a fact. We must dispel the myths surrounding young people, that they are irresponsible, disengaged, troublemakers, or do not have the experience to create real impact. Even in the most adverse of circumstances we have seen young people rising to the challenge and leading the way — from humanitarian crises to COVID-19 response. There is no doubt that we need young people’s innovation, drive, creativity and – more than anything – unwavering optimism that a better world is possible for everyone.”

ENDS

*https://www.ipu.org/our-impact/youth-empowerment/data-youth-participation

**The Be Seen Be Heard Global Youth Survey

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230108005001/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release

Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye